Zealand Pharma's shares fell sharply during trading, dropping -26.9% to DKK 238.7 as the American Diabetes Association's 2026 Scientific Sessions in New Orleans concluded. The conference - held June 5-8 - had been a near-term focal point for the Danish biotech, which presented Phase 2 ZUPREME-1 results for petrelintide, an amylin analog developed in collaboration with Roche.
The 42-week ZUPREME-1 trial reported that participants receiving petrelintide experienced clinically meaningful reductions in body weight versus placebo. The treatment was also associated with improvements in cardiometabolic risk factors, and investigators described a tolerability profile that was generally similar to placebo. Despite those findings, the data were broadly consistent with expectations that the market had already priced in, and investor enthusiasm dissipated once the presentation concluded.
Investor reaction was compounded by an analyst downgrade issued before the ADA event wrapped up. Cantor Fitzgerald lowered its rating on the company to Neutral from Overweight, pointing to limited differentiation for petrelintide. The firm highlighted that petrelintide produced roughly 9% placebo-adjusted weight loss at 42 weeks - a level comparable to cagrilintide and notably below Eli Lilly's eloralintide. Cantor Fitzgerald also noted the absence of a dose response in the data and argued that this provides no evidence weight-loss performance will improve in Phase 3. The firm suggested those factors raise the risk that petrelintide could enter the market as a third-to-market monotherapy with limited differentiation, reversing its earlier bullish view.
Deutsche Bank maintained a Hold rating on Zealand, with a price target of DKK 300. Analyst Emmanuel Papadakis said that the DKK 300 target equates to approximately a 30% discount to the bank's base-case net present value for the company, with the discount reflecting challenging pipeline prospects and long timelines to commercialization.
Competition in the obesity and amylin analog space presents a significant headwind. Eli Lilly's eloralintide is already in Phase 3 and is reported to have superior efficacy, while Novo Nordisk has advanced cagrilintide monotherapy into Phase 3. These programs represent two of Zealand's most direct rivals for petrelintide and were cited in market discussion as factors that limit the drug's potential to stand out.
Wider market conditions offered little support. U.S. equities traded under pressure during the same session, with the NASDAQ down -4.2% and the S&P 500 off -2.6%. That risk-off environment typically weighs more heavily on speculative biotechnology stocks, amplifying downside when company-specific news fails to exceed expectations.
The combination of a classical sell-the-news response after the ADA presentation, a recent analyst downgrade that questioned petrelintide's competitive profile, and a deteriorating macro backdrop converged to produce one of the steepest single-day drops for the stock in recent memory. Zealand's share price has shown elevated volatility over the past three months relative to the Danish market, with weekly volatility higher than 75% of Danish-listed stocks - a profile that accentuated the move toward the lower end of its 52-week trading range.
Context and implications
Market participants interpreted the Phase 2 readout as largely confirming expectations rather than delivering a surprise positive outcome that could materially re-rate the equity. The Cantor Fitzgerald downgrade underscored investor concern about differentiation and future upside potential for petrelintide, while Deutsche Bank's Hold rating and discounted price target highlighted longer-term commercialization and pipeline uncertainties. In the immediate term, competitive developments from companies already in Phase 3 exacerbated investor caution.
Where things stand
At the close of trading on the day the ADA meeting ended, Zealand's shares were down sharply and the stock's recent relative volatility suggested heightened investor sensitivity to both clinical-readout nuance and external market moves. Going forward, the dynamics described by analysts and the crowded competitive field will continue to shape investor expectations and the company's pathway to potential approval and commercial launch.